Distribution of an orphan drug

The company began with distribution of targeted cancer immunotherapy, innovative and original medicine used for the treatment of high risk neuroblastoma, a rare form of cancer arising from neural crest cells, the most frequently-occurring solid tumour in infants under the age of one. This innovative medicine that is becoming standard care in the treatment of high risk neuroblastoma is now also available in Serbia, it is a vital step forward in the treatment of young children with this aggressive type of cancer. The company became member of Group of pharmaceutical wholesalers within Serbian Chamber of Commerce, which has the status of full member of GIRP- the European Healthcare Distribution Association.